ISIgor N. Sychev

Igor N. Sychev

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Igor N. Sychev has a total of 127 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Polymorphic Brain Damage As a Leading Manifestation of the Debut of Infective Endocarditis: Case Report

    by O.V. Vasileva, M.N. Nazarova, G.K. Kiyakbaev, A.V. Piskun, L.A. Krichevskiy, I.N. Sychev, S.а. Rachina, N.A. Ananicheva, S.N. Tarasenko, S.S. Mirzakhamidova, et al.

    INTRODUCTION. Infectious endocarditis is characterized by high mortality and diverse clinical manifestations. The lesions of the nervous system in infectious endocarditis occurs in 60-80% of cases and can range from asymptomatic to severe presentations. The defeat of the nervous system in IE is often caused by ischemic strokes and intracerebral hemorrhages. CASE PRESENTATION. We present the young patient with recurrent infectious endocarditis, whose debut was marked by fever and severe cerebral symptoms. Сomputer and magnetic resonance imaging scans of the brain revealed intracerebral hemorrhage in the left occipital lobe and multiple focal lesions suggestive of an intracranial infection. It became necessary to conduct surgical treatment of infectious endocarditis due to appearance of symptoms and rapid progression of heart failure despite appropriate antibiotic therapy. The intracerebral hemorrhage has become a major obstacle to surgical treatment of infectious endocarditis. The article shows how the solutions adopted by the multidisciplinary team allowed to solve this problem.

  • Open Access

    Diagnosis and antimicrobial therapy of infections caused by polyresistant microorganisms (updated 2024)

    by V. B. Beloborodov, O. V. Goloshchapov, V. G. Gusarov, A. V. Dekhnich, M. N. Zamyatin, K. N. Zolotukhin, N. A. Zubareva, S. K. Zyryanov, D. A. Kamyshova, N. N. Klimko, et al.

    Strains of microorganisms characterized by resistance to antimicrobial drugs used in medical organizations continue to spread in most regions of the world, including Russia. This naturally affects both the effectiveness of antimicrobial therapy and the tactics of its use not only in adults but also in children. The coronavirus pandemic has highlighted the growing problems with the treatment of invasive mycoses, the selection of dosage of antibacterial agents when using sorption and dialysis therapy methods. In combination with the registration of new antibacterial drugs ABSTRACT in Russia, this necessitated the need to make adjustments to the Methodological recommendations “Diagnostics and Antimicrobial Therapy of Infections Caused by Polyresistant Strains of Microorganisms” (2nd edition), prepared by a group of leading Russian experts in 2022 [1]. The presented version was approved in December 2024 at a joint meeting of representatives of public organizations: the Russian Association of Anesthesiologists-Intensivists, the Interregional public organization “Alliance of Clinical Chemotherapists and Microbiologists”, the Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy (IACMAC), the public organization “Russian Sepsis Forum”. These recommendations reflect the interdisciplinary consensus opinion on approaches to the diagnosis and antimicrobial therapy of infections caused by polyresistant microorganisms.


  • Open Access

    Single-point multicenter survey of using antimicrobial drugs in the ICUs of Russian multidisciplinary hospitals: results of the Global-PPS 2022 project

    by Yu. A. Belkova, A. A. Kurkova, S. A. Rachina, R. S. Kozlov, E. N. Bochanova, E. V. Elokhina, S. K. Zyryanov, O. V. Ignatenko, E. S. Larin, G. G. Melkonyan, et al.

    Introduction. The marked increase in the resistance of infectious disease pathogens to antimicrobial drugs (AMDs), especially in intensive care units (ICUs), poses a threat to healthcare systems worldwide. This leads to adverse consequences: medical, social and economic. The objective was to evaluate the practice of AMDs using in the ICUs of Russian multidisciplinary hospitals based on its compliance with quality indicators.Materials and Methods. Single-point survey of AMDs using was conducted in 37 ICUs of various types in 12 multidisciplinary hospitals in different cities of the Russian Federation (Krasnoyarsk, Moscow (4 centres), Omsk, Saratov, Smolensk (2 centres), Tomsk, Yakutsk and Yaroslavl). The study was conducted in accordance with the protocol of international Global-PPS project from September to December 2022. The object of the study was the medical records of patients who received systemic AMDs for preventive or curative purposes. The practice of AMDs using was studies as well as the assessment of the prescription compliance with the quality indicators.Results. The survey included 501 patients of whom 314 (62.7%) received systemic AMDs. The frequency of AMDs prescription ranged from 24% in cardiac ICUs to 86.9% in surgical ICUs and reached 100% in paediatric departments. The vast majority of drugs were used for therapeutic purposes (74.3%–89.3%) and were prescribed for the treatment of nosocomial infections (71.6% on the average). Carbapenems (20.6%), third-generation cephalosporins (13.1%) and fluoroquinolones (11.6%) prevailed in the structure of prescriptions.Conclusion. The following accuracies in AMDs using were identified during our study: low frequency of etiotropic therapy, inappropriate duration of perioperative antibiotic prophylaxis and relatively low frequency of planning the duration of therapy. These accuracies provide an opportunity to optimize the practice of using drugs of this group in ICUs of hospitals participating in the study.


  • Open Access

    Clinical and economic assessment of nosocomial pneumonia antibacterial therapy in Moscow hospital

    by D. D. Ivanova, I. N. Sychev, N. B. Lazareva

    Objective: to conduct clinical and economic analysis of nosocomial pneumonia antibacterial therapy in a multidisciplinary hospital in Moscow.Material and methods. The medical records of patients admitted to Yudin City Clinical Hospital in Moscow in 2019–2021 were analyzed retrospectively. Pharmacoepidemiological analysis included the structure of prescriptions of antibacterial drugs (ABDs), features of empirical and etiotropic therapy, duration of using ABDa and other parameters. In total, 110 cases of severe nosocomial pneumonia caused by ESKAPE pathogens were selected for analysis. Direct medical costs and cost-effectiveness coefficients were calculated based on real world data.Results. It was established that nosocomial pneumonia is the most common complication among hospitalized patients in the intensive care unit (ICU). The etiology of nosocomial pneumonia was mostly presented by K. pneumoniae, A. Baumanii, and P. aeruginosa. The administered ABDs included 31 international nonproprietary names of the group J01 Systemic antibacterial drugs. The direct medical costs of empirical antibacterial therapy averaged for 9367 rubles (2118 rubles [1462; 3525]). Comparative cost-effectiveness analysis was performed based on surrogate and endpoints. It was found that direct medical costs associated with ESKAPE pathogens spend about 70% of the budget of established tariff to pay for medical care of the compulsory health insurance program for the patient's stay in the ICU.Conclusion. Antibacterial therapy costs for nosocomial pneumonia significantly increase the total cost of a patient's hospital stay. Сlinical and economic assessment of drug use help optimize therapy costs and develop a hospital formulary of antimicrobial drugs.

  • Open Access

    A pilot study of the clinical significance and outcomes of infections in the ICU caused by colistin-resistant Klebsiella pneumoniae

    by I. N. Sychev, O. V. Ignatenko, S. V. Yakovlev, L. V. Fedina, E. N. Burmistrova, M. P. Suvorova, T. D. Rastvorova, E. V. Strigunkova, R. Kh. Mukhamadiev

    The objective was to study the risk factors, outcomes of infections caused by colistin-resistant K. pneumonia (CRKP) and to evaluate the sensitivity of these microorganisms to antibacterial agents to determine the most adequate antibiotic therapy options.Materials and methods. Klebsiella pneumoniae strains isolated in the ICU of an acute care hospital between October 2020 and August 2022 were included in the study. Microorganisms were identified using an automatic analyzer PHOENIX. The determination of antibiotic sensitivity was studied by the method of serial micro-dilutions in agar with the determination of MIC EUCAST criteria were used to interpret sensitivity. Detection of carbapenemases was carried out by PCR. Clinical efficacy of starter therapy was evaluated as recovery/improvement and no effect.Results. The infection was characterized by a severe course in 58.9 % of patients, with SOFA scores ranging from 1 to 16 points (mean 5.8 points). 88.2 % of patients had received prior antibiotics, most commonly carbapenems. CRKP infections occurred more frequently in older men with comorbidity. The clinical efficacy of initial antibiotic therapy was 41.2 %. In 47.1 % of cases, there was no effect, which required adjustment of therapy. Excluding patients in whom it was impossible to evaluate the effect, eradication was achieved in 33.3 % of patients. 64.6 % of patients were discharged or transferred to another hospital; 6 patients died between 5 and 41 days after diagnosis of CRKP infection. Fatal outcome was more frequent in women ( p=0.042), patients with higher comorbidity index (p=0.027), in case of sepsis and/or septic shock ( p=0.011), and in earlier detection of CRKP after hospitalization ( pConclusion. The efficacy of initial antibiotic therapy after detection of CRKP infection has been shown to be associated with patient survival and reduced risk of mortality with an odds ratio of 3.5. We also identified risk factors for mortality in CRKP infection: comorbidity, sepsis, duration of hospitalization and female gender.


  • Open Access

    Diagnosis and antibiotic therapy of nosocomial pneumonia in adults: from recommendations to real practice. A review

    by Svetlana А. Rachina, Ludmila V. Fedina, Marina V. Sukhorukova, Igor N. Sychev, Egor S. Larin, Abdulbari A. Alkhlavov

    Nosocomial pneumonia is a healthcare-associated infection with significant consequences for the patient and the healthcare system. The efficacy of treatment significantly depends on the timeliness and adequacy of the antibiotic therapy regimen. The growth of resistance of gram-negative pathogens of nosocomial pneumonia to antimicrobial agents increases the risk of prescribing inadequate empirical therapy, which worsens the results of patient treatment. Identification of risk factors for infection with multidrug-resistant microorganisms, careful local microbiological monitoring with detection of resistance mechanisms, implementation of antimicrobial therapy control strategy and use of rational combinations of antibacterial drugs are of great importance. In addition, the importance of using new drugs with activity against carbapenem-resistant strains, including ceftazidime/aviabactam, must be understood. This review outlines the current data on the etiology, features of diagnosis and antibacterial therapy of nosocomial pneumonia.


  • Open Access

    Anticoagulant therapy with apixaban based on a pharmacogenetic approach: a course to safety

    by L. V. Fedina, I. N. Sychev, N. P. Denisenko, Sh. P. Abdullaev, K. B. Mirzaev, D. A. Sychev

    For the past 60 years, vitamin K antagonists (VKAs) have been the main drugs used for long-term oral anticoagulant therapy. Because of the significant limitations of AVCs, direct-acting oral anticoagulants (DOAKs) have been developed over the past decade. DOAKs have a predictable pharmacokinetic profile and lack the disadvantages of vitamin K antagonists. Apixaban is an oral direct-acting factor Xa inhibitor used for the prevention of thromboembolic complications in patients with non-valvular atrial fibrillation (AF) and deep vein thrombosis. Despite the use of recommended dosages, some patients may still experience bleeding or lack the desired anticoagulant effect. With this in mind, it is critical to explore new uses for direct oral anticoagulants and to predict their dosage when used in monotherapy or in combination with other drugs. In addition, recent studies have documented individual variability in plasma POAC levels. DOAC pharmacogenetics is a relatively new area of research. There is a need to understand the role of pharmacogenetics in adapting anticoagulant therapy according to a patient’s genetic characteristics. In this scientific review of current data, we detail the pharmacokinetics and pharmacogenetics of apixaban as well as new data concerning the clinical characteristics that predetermine the necessary dosage and risk of adverse drug reactions (ADRs). Indeed, the results obtained to date from basic and clinical studies certainly indicate an undeniable influence of genomic changes on the pharmacokinetics of POACs.

  • Open Access

    Clinical and pharmacological approaches to personalization of the prescription of oral anticoagulants: clinical cases

    by L. V. Fedina, I. N. Sychev, T. D. Rastvorova, K. B. Mirzaev, D. A. Sychev

    Anticoagulants play an important role in reducing complications and mortality associated with thromboembolic disease. For some time, vitamin K antagonists (VKAs) have been the main drugs used for long-term oral anticoagulant therapy, but because of the significant limitations of VKAs over the past decade, pharmacological research has led to the development of new direct actingoral anticoagulants (DOACs). Direct-acting oral anticoagulants have a rapid onset of action with peak levels within 2–4 hours and a half-life of about 12 hours, which is much shorter than that of vitamin K antagonists, a more predictable anticoagulant effect, no need for dose selection, routine laboratory monitoring of pharmacodynamic effects, and a lower frequency of clinically significant drug-drug interactions compared with warfarin. But anticoagulants can still cause serious adverse drug reactions (ADRs) in the form of hemorrhagic complications in hospitalized patients, as confirmed in studies. Currently, clinical-pharmacological technologies of personalized medicine such as pharmacogenetic and pharmacokinetic studies are considered as promising approaches to improve the safety of modern pharmacotherapy, allowing the prediction and prevention of various ADRs. In addition, there are emerging studies showing the importance of genetic features of patients in relation to the metabolism of oral anticoagulants, as well as described clinical situations where different gene polymorphisms, could be responsible for changes in the pharmacokinetics of DOACs. This article reviews clinical cases in which pharmacogenetic testing and therapeutic drug monitoring are used to optimize the clinical efficacy and maximum safety of anticoagulant therapy with apixaban and rivaroxaban.

  • Open Access

    Analysis of the structure of bacteremia and sensitivity to antibiotics of microorganisms isolated in intensive care units in an emergency hospital in the period from 2003 to 2021: a retrospective observational study

    by А. О. Bykov, M. P. Suvorova, D. N. Protsenko, Sergey V. Yakovlev, O. V. Ignatenko, E. N. Burmistrova, I. N. Sychev, N. P. Krotenko, Сергей Владимирович Яковлев

    INTRODUCTION: Creation of protocols for effective empiric antimicrobial therapy is impossible without the analysis of current antibiotic susceptibility data. OBJECTIVE: Analysis of changes in the etiological significance of the leading pathogens of bacteremia in the ICU (intensive care unit) in the period from 2003 to 2021, and their sensitivity to antibiotics; study of the types of carbapenemases in the most relevant pathogens — Klebsiella pneumoniae and Acinetobacter baumannii. MATERIALS AND METHODS: The analysis included all microorganisms isolated from the blood of patients who were in the medical 12-bed ICU in the emergency hospital of Moscow in the period from 2003 to 2021. Identification of microorganisms and determination of antibiotic sensitivity were carried out with an automatic PHOENIX analyzer and a standardized disco diffusion method. Detection of carbapenemases was carried out by PCR (polymerase chain reaction). RESULTS: In the period from 2003 to 2021, 17 034 blood samples were examined, from which 6372 microorganisms were isolated. During this period, the proportion of Gram-negative microorganisms increased from 21.0 to 52.8 %, mainly due to K. pneumoniae from 1.0 to 24.5 % and A. baumannii from 0 to 9.1 %. The resistance of these microorganisms to carbapenems increased significantly from 2008 to 2021: K. pneumoniae from 2.3 % to 70.3 %, A. baumannii — from 7.5 to 99.5 %. K. pneumoniae produced the following types of carbapenemases: OXA-48 (73.8 %), KPC (6.2 %), NDM 1.5 %, NDM + OXA-48 (15.4 %), KPC + OXA-48 (3.1 %). All A. baumannii strains produced OXA-40 type carbapenemase. OXA-48 carbapenemase producers were resistant to colistin and tigecycline in 14.6 and 44.8 %, and to ceftazidime/avibactam in 4.2 %. CONCLUSIONS: The increased level of antimicrobial resistance in recent years among Gram-negative microorganisms isolated from blood is a very significant problem in the ICU. Most K. pneumoniae strains are characterized as multi-drug resistant, about 10 % of the strains were categorized as extremely-drug resistant (XDR) or pan-drug resistant. All strains of A. baumannii belong to the category of XDR.


  • Open Access

    The First Experience of Combined Use of Cefepime/Sulbactam and Aztreonam in ICU Patients with Nosocomial Infections Caused by Carbapenem-Resistant Gram-Negative Microorganisms Producing Class B and D Carbapenemases

    by M. P. Suvorova, I. N. Sychev, O. V. Ignatenko, E. N. Burmistrova, S. S. Mirzakhamidova, L. V. Fedina, R. M. Vakolyuk, S. V. Yakovlev

    Background. The difficulties of antibacterial therapy of infections caused by carbapenemase-producing gram-negative bacteria are associated with limited options for adequate therapy since, in addition to resistance to carbapenems and other beta-lactams, these microorganisms are often characterized by associated resistance to other classes of antibiotics, including polymyxins. In vitro data support the idea of combined use of inhibitor-protected cephalosporins with aztreonam for the treatment of such infections. The aim of the study was to investigate the effectiveness of cefepime/sulbactam (FEP/SB) in combination with aztreonam (ATM) in infections caused by class B and D carbapenemase producers.Methods. A prospective observational study evaluated the effectiveness of the combination of FEP/SB + ATM in ICU patients with nosocomial infections complicated by sepsis or septic shock caused by carbapenem-resistant pathogens with documented production of class B or D carbapenemase. The ineffectiveness of previous treatment and the absence of other options for adequate therapy were used as inclusion criteria. Microbiological, clinical efficacy, and 30-day mortality were indicators of therapy evaluation.Results. The study included 25 patients with nosocomial infection (76% of them was VAP), with sepsis (60%) or septic shock (40%) and an average SOFA score of 6 points caused by Klebsiella pneumoniae (23 patients) or Pseudomonas aeruginosa (2) producing carbapenemases OXA-48 (56%), NDM (20%), NDM + OXA-48 (16%), and class B carbapenemase in two strains of P. aeruginosa. The average daily dose of FEP/SB and ATM was 6.6 g, the duration of therapy was 9.9 days. As a result of the treatment, eradication was achieved in 68% of patients, clinical efficacy was 72%, and the 30-day mortality rate was 28%.Conclusion. Our results show good clinical and bacteriological efficacy of the combination of FEP/SB and ATM in infections caused by extremely resistant K. pneumoniae, non-susceptible to carbapenems and producing class B or D carbapenemase.